Sorrento Therapeutics Inc (CE) (SRNE) Actualités

Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations...

Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment...

Sorrento Therapeutics, Inc. and IGDRASOL Announce Three Presentations on Cynviloq™ (IG-001; paclitaxel polymeric micelle) a...

Sorrento Therapeutics, Inc. and IGDRASOL Announce Three Presentations on Cynviloq™ (IG-001; paclitaxel polymeric micelle) at the American...

Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL

Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL Transaction establishes a pipeline led by IGDRASOL's late clinical stage...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Amended Statement of Beneficial Ownership (SC 13D/A)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D/A Under the Securities...

- Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Quarterly Report (10-Q)

Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 10-Q  ...

- Quarterly Report (10-Q)

Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 10-Q  ...

- Confidential Treatment Order (CT ORDER)

Awarepoint, Leading RTLS Provider for Hospitals, Continues Staffing Up for Growth

Awarepoint, Leading RTLS Provider for Hospitals, Continues Staffing Up for Growth Stephen Zaniboni, formerly of XIFIN, Inc., joins as CFO and...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...